Literature DB >> 10445998

The epidemiological impact of antimeningococcal B vaccination in Cuba.

A P Rodriguez1, F Dickinson, A Baly, R Martinez.   

Abstract

The incidence of invasive meningococcal disease (IMD) before (1984-1988) and after (1989-1994), a nationwide intervention with VA-MENGOC-BC vaccination started in 1989, was compared. The prevaccination period incidence density (ID> 8.8/10(5) year-person) was higher than the postvaccination ID (ID< 6.5/10(5) year-person). The percentage proportional differences from the start to the end of each period of ID in the vaccinal period was higher (87%) than the prevaccinal (37%) with significant differences among vaccinated groups (< 25 years old). A break-point (Chow test) was confirmed by the decrease in the ID between 1989 and 1990 in children under 1 year old, 5-9, 10-14, 15-19 and 50-54 years. Comparison of ID using maps showed a decrease in IMD in all municipalities during the postvaccination period. These findings support the epidemiological impact of VA-MENGOC-BC vaccination in the reduction of IMD morbidity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10445998     DOI: 10.1590/s0074-02761999000400002

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  19 in total

1.  Community acquired bacterial meningitis in Cuba: a follow up of a decade.

Authors:  Antonio E Pérez; Félix O Dickinson; Misladys Rodríguez
Journal:  BMC Infect Dis       Date:  2010-05-25       Impact factor: 3.090

Review 2.  Vaccine-induced pathogen strain replacement: what are the mechanisms?

Authors:  Maia Martcheva; Benjamin M Bolker; Robert D Holt
Journal:  J R Soc Interface       Date:  2008-01-06       Impact factor: 4.118

Review 3.  Neisseria meningitidis: biology, microbiology, and epidemiology.

Authors:  Nadine G Rouphael; David S Stephens
Journal:  Methods Mol Biol       Date:  2012

4.  Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.

Authors:  Jamie Findlow; Stephen Taylor; Audun Aase; Rachel Horton; Robert Heyderman; Jo Southern; Nick Andrews; Rita Barchha; Ewan Harrison; Ann Lowe; Emma Boxer; Charlotte Heaton; Paul Balmer; Ed Kaczmarski; Philipp Oster; Andrew Gorringe; Ray Borrow; Elizabeth Miller
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 5.  Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease.

Authors:  Darryl J Hill; Natalie J Griffiths; Elena Borodina; Mumtaz Virji
Journal:  Clin Sci (Lond)       Date:  2010-02-09       Impact factor: 6.124

Review 6.  Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

Authors:  Caroline L Trotter; Martin C J Maiden
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

7.  Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba.

Authors:  Yanet Climent; Daniel Yero; Isabel Martinez; Alejandro Martín; Keith A Jolley; Franklin Sotolongo; Martin C J Maiden; Rachel Urwin; Rolando Pajón
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

Review 8.  The epidemiology of meningococcal disease in Latin America 1945-2010: an unpredictable and changing landscape.

Authors:  M A P Sáfadi; S González-Ayala; A Jäkel; H Wieffer; C Moreno; A Vyse
Journal:  Epidemiol Infect       Date:  2012-08-09       Impact factor: 2.451

9.  Meningococcal disease: changes in epidemiology and prevention.

Authors:  Qiuzhi Chang; Yih-Ling Tzeng; David S Stephens
Journal:  Clin Epidemiol       Date:  2012-09-19       Impact factor: 4.790

10.  Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010.

Authors:  Ana Belén Ibarz-Pavón; Ana Paula Lemos; Maria Cecilia Gorla; Mabel Regueira; Jean-Marc Gabastou
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.